Bioral® Technology

Bioral® is a novel drug delivery system, based upon cochleate technology.

Bioral® encapsulates and protects a drug without chemically bonding to it and may facilitate oral dosing of drugs that typically need to be given by intravenous administration. Alternating layers of lipids spiral around a drug molecule, encapsulating it and potentially protecting it from degradation by acid or digestive enzymes in the stomach. The Bioral® technology is being evaluated as a new means of overcoming the poor oral absorption of drugs, such as the antifungal drug Amphotericin B and in programs involving siRNAs. Several pre-clinical studies have demonstrated the potential value of agents delivered using the Bioral® technology.1, 2, 3

The Bioral® drug delivery technology was developed in collaboration with the University of Albany and the University of New Jersey Medical and Dental School, each of which has granted BDSI exclusive worldwide licenses under applicable patents. Collaboration with the National Institutes of Health has supported, in part, the Bioral® preclinical program, and a collaboration with the Walter Reed Army Institute of Research is currently exploring the use of Bioral® technology in difficult to treat parasitic infections.

1 Campo, et al. Efficacy of a Nanocochleate-Encapsulated 3,5-Diaryl-s-Triazole Derivative in a Murine Model of Graft-Versus-Host Disease. Transplantation, Vol 86, Number 1, July 15, 2008.

2 Delmas G, Park S, Chen ZW, Tan F, Kashiwazaki R, Zarif L, Perlin DS.  Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother. 2002 Aug;46(8):2704-7.

3 Santangelo R, Paderu P, Delmas G, Chen ZW, Mannino R, Zarif L, Perlin DS.  Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis. Antimicrob Agents Chemother. 2000 Sep;44(9):2356-60.